The 10-second takeaway
For the quarter ended June 30 (Q2), Nxstage Medical beat slightly on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded. GAAP loss per share dropped.
Gross margins grew, operating margins dropped, net margins grew.
Nxstage Medical reported revenue of $65.5 million. The 12 analysts polled by S&P Capital IQ expected to see sales of $64.5 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $59.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.06. The 11 earnings estimates compiled by S&P Capital IQ averaged -$0.07 per share. GAAP EPS were -$0.06 for Q2 versus -$0.09 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 38.3%, 40 basis points better than the prior-year quarter. Operating margin was -6.5%, 90 basis points worse than the prior-year quarter. Net margin was -5.2%, 340 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $67.6 million. On the bottom line, the average EPS estimate is -$0.06.
Next year's average estimate for revenue is $266.1 million. The average EPS estimate is -$0.26.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 137 members out of 168 rating the stock outperform, and 31 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Nxstage Medical a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $15.65.
Is Nxstage Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Nxstage Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends NxStage Medical. The Motley Fool owns shares of NxStage Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.